Historically, rheumatologists have been hesitant to combine biologics in our patients, based largely on trials from 20 years ago that found an increased risk of serious infections when combining a TNF inhibitors and an IL1 inhibitor, or abatacept and another biologic. With the availability of newer ...

I agree with Dr. Ruderman’s thoughtful answer. However, it should be noted that rare cases of IBD onset and exacerbation have been reported, especially in the setting of psoriasis and psoriatic arthritis, in patients on IL-17 inhibitors. This highlights the need to be vigilant and to select pa...